Pathogenetic aspects of optimization of therapy of chronic obstructive pulmonary disease attacks


DOI: https://dx.doi.org/10.18565/therapy.2020.2.48-53

Zaykova-khelimskaya I.V., Kostenko D.Yu.

Far Eastern State Medical University of the Ministry of Healthcare of Russia, Khabarovsk
The aim of the study is examination of the correlation between the level of secretory protein of bronchiolar exocrinocytes (spBEC-16) in the blood and the clinical characteristics of patients with chronic obstructive pulmonary disease (COPD) during the exacerbation period, as well as the analysis of changes in the studied parameters against the background of azoximer bromide intake.
Material and methods. 90 patients with COPD exacerbation were divided into two groups: group A (n = 45) received standard therapy while COPD exacerbation; group B (n = 45) in addition to standard therapy received an oral form of azoximer bromide. The paper investigated the effect of Azoximer bromide on the level of spBEc-16 in serum of patients with exacerbation of COPD and the effect of spBEc-16 on the severity of symptoms of COPD in the dynamics of international questionnaires CAT-test and mMRC.
Results and conclusion. The findings demonstrated that the inclusion of the Azoximer bromide in standard COPD therapy caused a significant increase of serum spBEc-16 at the end of treatment. The inclusion of Azoximer bromide in COPD therapy reduced the impact of the disease on patients ‘ lives and the intensity of breathlessness.
Keywords: Azoximer bromide, secretory protein of bronchiolar exocrinocytes-16, exacerbation of COPD, COPD
Read entire article

Literature


  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. [Electronic source]. Available at: https://goldcopd.org (reference date 23.12.2019).

  2. Всемирная организация здравоохранения 2018. [Электронный источник]. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death (дата обращения 23.12.2019). [World Health Organization 2018. [Electronic source]. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death (reference date 23.12.2019) (In Russ.)].

  3. Wang H., Naghavi M., Allen C. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388: 1459–544. doi: 10.1016/S0140-6736(16)31012-1.

  4. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963–74. doi: 10.2147/COPD.S67283.

  5. Федеральные клинические рекомендации по хронической обструктивной болезни легких. Российское респираторное общество. Под ред. А.Г. Чучалина. 2018; 72 с. [Электронный источник]. Режим доступа: http://cr.rosminzdrav.ru/#!/recomend/908 (дата обращения 23.12.2019). [Federal clinical guidelines on chronic obstructive pulmonary disease. Russian Respiratory Society. Edited by Chuchalin A.G. 2018; 72 p. [Electronic source]. Available at: http://cr.rosminzdrav.ru/#!/recomend/908 (reference date 23.12.2019) (in Russ.)].

  6. Laucho-Contreras M.E., Polverino F., Gupta K. et al. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir J. 2015; 45(6): 1544–56. doi: 10.1183/09031936.00134214.

  7. Gamez A.S., Gras D., Petit A. et al. Supplementing defect in club cell secretory protein attenuates airway inflammation in COPD. Chest. 2015; 147(6): 1467–76. doi: 10.1378/chest.14-1174.

  8. Боркина А.Н. Структурно-функциональная реорганизация секреторных экзокриноцитов (клеток Клара) и альвеолоцитов 2 типа при воздействии дестабилизирующих факторов и при хронической обструктивной болезни легких: Автореф. ... дис. канд. мед. наук. Оренбург. 2008; 22 с. [Borkina A.N. Structural and functional reorganization of secretory exocrinocytes (Clara cells) and II type alveolocytes under the influence of destabilizing factors in COPD. Author’s abstract of dissertations of candidate of medical science. Orenburg. 2008; 22 p. (In Russ.)].

  9. Zhu L., Di P.Y., Wu R. et al. Repression of CC16 by cigarette smoke (CS) exposure. PLoS One. 2015; 10(1): e0116159. doi:10.1371/journal.pone.0116159.

  10. Анаев Э.Х. Биологические маркеры при хронической обструктивной болезни легких. Практическая пульмонология. 2018; 1: 26–32. [Anaev E.Kh. Biological markers of chronic obstructive pulmonary disease. Prakticheskaya pul'monologiya. 2018; 1: 26–32 (In Russ.)].

  11. Snyder J.C., Reynolds S.D., Hollingsworth J.W. et al. Clara cells attenuate the inflammatory response through regulation of macrophage behavior. Am J Respir Cell Mol Biol. 2010; 42(2): 161–71. doi: 10.1165/rcmb.2008-0353OC.

  12. Cortjens B., van Woensel J.B., Bem R.A. Neutrophil extracellular traps in respiratory disease: guided anti-microbial traps or toxic webs? Paediatr Respir Rev. 2017; 21: 54–61. doi:10.1016/j.prrv.2016.03.007.

  13. Liu T., Wang F.P., Wang G., Mao H. Role of neutrophil extracellular traps in asthma and chronic obstructive pulmonary disease. Chin Med J (Engl). 2017; 130(6): 730–36. doi:10.4103/0366-6999.201608.

  14. Langereis J.D., Hermans P.W. Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett. 2013; 346(2): 81–89. doi:10.1111/1574-6968.12203.

  15. Исаева Е.И, Ветрова Е.Н, Тюшева В.В. с соавт. Изучение противовирусной активности азоксимера бромид на экспериментальной модели in vitro. Журнал инфектологии. 2019; 11(1 S1): 5–13. [Isaeva E.I., Vetrova E.N., Tyusheva V.V. et al. Study of antiviral activity of azoximer bromide on an experimental in vitro model. Zhurnal infektologii. 2019; 11(1 S1): 5–13 (In Russ.)].

  16. Пинегин Б.В., Дагиль Ю.А., Воробьева Н.В., Пащенков М.В. Влияние азоксимера бромида на формирование внеклеточных нейтрофильных ловушек. РМЖ. 2019; 1–2: 42–46. [Pinegin B.V., Dagil Yu.A. Vorobyova N.V., Paschenkov M.V. Impact of azoximer bromide on formation of neutrophil extracellular traps. Russkiy meditsinskiy zhurnal. 2019; 1–2: 42–46 (In Russ.)].


About the Autors

Irina V. Zaykova-Khelimskaya, MD, associate professor, professor of the Department of hospital therapy of Far Eastern State Medical University of the Ministry of Healthcare of Russia. Address: 680000, Khabarovsk, 35 Karl Marx Str. E-mail: irinavh@mail.ru
Dmitry Yu. Kostenko, correspondence post-graduate student of the Department of hospital therapy of Far Eastern State Medical University of the Ministry of Healthcare of Russia. Address: 680000, Khabarovsk, 35 Karl Marx Str. E-mail: mitiacostencko@yandex.ru


Similar Articles

Back to Content

Бионика Медиа